Niemeijer et al. (9) (NCT03065764) | 89Zr-pembrolizumab PET | Non–small cell lung cancer | 12 | 89Zr-pembrolizumab PET is feasible and safe; 89Zr-pembrolizumab uptake is higher in patients with treatment response; 89Zr-pembrolizumab uptake did not correlate with PD-1/PD-L1 expression |
Bensch et al. (10) (NCT02453984) | 89Zr-atezolizumab PET | Locally advanced or metastatic solid tumors | 22 | 89Zr-atezolizumab PET is feasible and safe; 89Zr-atezolizumab uptake correlates with PD-L1 expression; 89Zr-atezolizumab SUVmax predicts response to atezolizumab, including overall and progression-free survival, better than PD-L1 expression assessed by immunohistochemistry |
Niemeijer et al. (11) (2015-004760-11) | 18F-PD-L1 PET; 89Zr-nivolumab PET | Non–small cell lung cancer | 13 | 18F-PD-L1 and 89Zr-nivolumab PET is feasible and safe; 18F-PD-L1 uptake correlates with tumor PD-L1 expression; 89Zr-nivolumab uptake correlates to PD-1 expression on lymphocytic aggregates; 89Zr-atezolizumab SUVpeak correlates with treatment response (responders vs. nonresponders based on RECIST, version 1.1) |